DiaMedica Therapeutics Inc.

DMAC | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.26

+$0.41 (+5.99%)

At close: Sep 21, 2026, 4:00 PM ET

$7.26

$0 (0.00%)

After-hours: Sep 21, 2026, 4:10 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $391.19M

Enterprise Value $347.87M

Beta 0.97

Average Volume 185.19K

Shares Outstanding (Diluted) 53.89M

Shares Change YoY 25.46%

Institutional Ownership 21.75%

Exchange NASDAQ

ISIN CA25253X2077

Price Performance

Price Change 1M 12.6%

Price Change 3M 15.6%

Price Change 6M 5.8%

Price Change YTD -8.4%

Price Change 1Y 4.0%

Price Change 3Y 159.3%

Price Change 5Y 85.2%

1M CAGR (ann.) 7.6%

1Y CAGR (ann.) 7.4%

5Y CAGR (ann.) 13.0%

All-Time CAGR -11.5%

Valuation

PE Ratio -10.08

Forward PE N/A

PEG Ratio 2.34

Forward PEG 3.45

PS Ratio N/A

Forward PS 176.20

PB Ratio 10.20

P/FCF Ratio -12.38

P/Adj. FCF Ratio -11.26

P/OCF Ratio -12.31

EV/Sales N/A

EV/EBIT -9.27

EV/EBITDA -9.38

EV/FCF -11.01

Earnings Yield -9.9%

FCF Yield -8.1%

Adj. FCF Yield -8.9%

Financial Health

Net Cash $43.32M

Total Debt $185K

Cash & Short-Term Investments $43.5M

Total Assets $45M

Current Ratio 6.72

Quick Ratio 6.72

Debt / Equity Ratio 0.00

Debt / EBITDA -0.01

Debt / FCF -0.01

OCF / Debt -170.63

Interest Coverage 0.00

Altman Z-Score 27.48

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -9.9%

Returns

Return on Assets -83.4%

Return on Equity -77.7%

Return on Invested Capital -100.9%

Return on Capital Employed -101.2%

Return on Tangible Assets -83.4%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y -30.3%

EPS CAGR 3Y -14.7%

EPS CAGR 5Y -4.6%

EPS CAGR 10Y 1.9%

FCF CAGR 3Y -22.9%

FCF CAGR 5Y -23.4%

FCF CAGR 10Y -20.4%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 6

EPS Growth Next 3Y -5.6%

Revenue Growth Next 3Y N/A

Earnings Date Nov 10, 2026

EPS Estimate (next Q) -$0.20

EPS Growth Est (next Q) 17.6%

Revenue Est (next Q) $13.5M

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $8.33

Price Target Upside 14.7%

Cash Flow

Operating Cash Flow $-31.57M

Free Cash Flow $-31.6M

Adj. Free Cash Flow $-34.73M

FCF Per Share -$0.59

OCF Per Share -$0.59

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-38.86M

EBITDA $-37.09M

Net Income $-37.54M

EPS (Diluted) -$0.72

Revenue / Employee N/A

Profit / Employee $-1.07M

Employees 35